Ed Vital, MD

University of Leeds
Leeds, United Kingdom

Professor of Translational Medicine at the University of Leeds. Primarily working on preclinical disease, translational immunology, clinical trials and musculoskeletal outcome measures. Chair of the BILAG group.

Presentation(s):

• 0654: Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); CESAS: Consultant (Ongoing); Dianthus: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Khmer: Consultant (Ongoing); Liatris: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Otsuka: Consultant (Ongoing); Ventus: Consultant (Ongoing), Consultant (Ongoing); Zenas: Consultant (Ongoing)

• 0801: Achieving Sustained Lupus Low Disease Activity State and Remission with Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis from a Phase II Study

  Sunday, October 26, 2025
  1:00 PM - 1:15 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); CESAS: Consultant (Ongoing); Dianthus: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Khmer: Consultant (Ongoing); Liatris: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Otsuka: Consultant (Ongoing); Ventus: Consultant (Ongoing), Consultant (Ongoing); Zenas: Consultant (Ongoing)

• 1526: Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); CESAS: Consultant (Ongoing); Dianthus: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Khmer: Consultant (Ongoing); Liatris: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Otsuka: Consultant (Ongoing); Ventus: Consultant (Ongoing), Consultant (Ongoing); Zenas: Consultant (Ongoing)

• 1525: Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); CESAS: Consultant (Ongoing); Dianthus: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Khmer: Consultant (Ongoing); Liatris: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Otsuka: Consultant (Ongoing); Ventus: Consultant (Ongoing), Consultant (Ongoing); Zenas: Consultant (Ongoing)

• 2393: Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study

  Tuesday, October 28, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); CESAS: Consultant (Ongoing); Dianthus: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Khmer: Consultant (Ongoing); Liatris: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Otsuka: Consultant (Ongoing); Ventus: Consultant (Ongoing), Consultant (Ongoing); Zenas: Consultant (Ongoing)